Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources S. Marciano, L. Haddad, S.M. Borzi, C. D’Amico, L.A. Gaite, M.V. Aubone, M.E. Sirotinsky, N. Ratusnu, M.S. Frola, M.C. Aparicio, B. Ríos, M.N. Anselmo, R. Hansen, S. De Filippi, C. García Dans, L. de Labra, M.A. Peche, T.M. Strella, M. Ibáñez Duran, M.B. García Rosales, M. Dirchwolf, O.A. Galdame, A.C. Gadano

Sofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review J.L. Pérez-Hernández, C.A. Arce-Salinas, R. Lehmann-Mendoza, A. Torre-Delgadillo, G.E. Castro-Narro, E. Cerda-Reyes, M.V. Ramos-Gómez, L. Juárez-Chavez, M. Dehesa-Violante, L.E. Muñoz-Espinoza, L.E. Cisneros-Garza, I. Aiza-Haddad, J.A. Velarde-Ruiz Velasco, R. Contreras-Omaña, N. García-Casarreal, A. Carmona-Castañeda, F. Higuera-de-la-Tijera

Risk factors for developing hepatocellular carcinoma in patients treated with direct-acting antivirals I. Santana-Salgado, A. Bautista-Santos, R. Moreno-Alcántar